Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: A phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy

Diabetes/Metabolism Research and Reviews

Volumn 27, Issue 4, 2011, Pages 392-401

  Henriksen, Kim ^a   Byrjalsen, Inger ^b   Qvist, Per ^a   Beck Nielsen, Henning ^c   Hansen, Gitte ^a   Riis, Bente J ^b   Perrild, Hans ^d   Svendsen, Ole Lander ^d   Gram, Jeppe ^e   Karsdal, Morten A ^a   Christiansen, Claus ^b  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d BISPEBJERG HOSPITAL   (Denmark)

^e ESBJERG HOSPITAL   (Denmark)

Author keywords

Balaglitazone; Efficacy; PPAR ; Safety; Type 2 diabetes

Indexed keywords

BALAGLITAZONE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO;

ADULT; ARTICLE; BODY COMPOSITION; BONE DENSITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FLUID RETENTION; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

AGED; BLOOD GLUCOSE; BODY COMPOSITION; BONE DENSITY; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PPAR GAMMA; QUINAZOLINES; THIAZOLIDINEDIONES; WATER-ELECTROLYTE BALANCE; WEIGHT GAIN;

EID: 79955730238     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1187     Document Type: Article

References (28)

1. World Health Organization. WHO Diabetes. Fact sheet no 312. WHO: Geneva, 2008.
2. Cho N, Momose Y. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress. Curr Top Med Chem 2008; 8: 1483-1507.
3. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373: 2125-2135.
4. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298: 1180-1188.
5. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
6. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653.
7. Nielsen R, Pedersen TA, Hagenbeek D, et al. Genome-wide profiling of PPARgamma: RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis. Genes Dev 2008; 22: 2953-2967.
8. Charbonnel B, DeFronzo R, Davidson J, et al. Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19). J Clin Endocrinol Metab 2010; 95: 2163-2171.
9. Takada I, Suzawa M, Matsumoto K, Kato S. Suppression of PPAR transactivation switches cell fate of bone marrow stem cells from adipocytes into osteoblasts. Ann N Y Acad Sci 2007; 1116: 182-195.
10. Karalliedde J, Buckingham RE. Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies. Drug Saf 2007; 30: 741-753.
11. Soroceanu MA, Miao D, Bai XY, Su H, Goltzman D, Karaplis AC. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 2004; 183: 203-216.
12. Berger JP, Akiyama TE, Meinke PT. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 2005; 26: 244-251.
13. Larsen PJ, Lykkegaard K, Larsen LK, et al. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone. Eur J Pharmacol 2008; 596: 173-179.
14. Henriksen K, Byrjalsen I, Nielsen RH, et al. A comparison of glycemic control, water retention, and musculoskeletal effects of balaglitazone and pioglitazone in diet-induced obese rats. Eur J Pharmacol 2009; 616: 340-345.
15. Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002; 56: 251-257.
16. Davidson JA, Perez A, Zhang J. Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study. Diabetes Obes Metab 2006; 8: 164-174.
17. Berhanu P, Perez A, Yu S. Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy. Diabetes Obes Metab 2007; 9: 512-520.
18. Mattoo V, Eckland D, Widel M, et al. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study. Clin Ther 2005; 27: 554-567.
19. Carver C. Insulin treatment and the problem of weight gain in type 2 diabetes. Diabetes Educ 2006; 32: 910-917.
20. Erdmann E, Charbonnel B, Wilcox RG, et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 2007; 30: 2773-2778.
21. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007; 298: 1189-1195.
22. McDonough AK, Rosenthal RS, Cao X, Saag KG. The effect of thiazolidinediones on BMD and osteoporosis. Nat Clin Pract Endocrinol Metab 2008; 4: 507-513.
23. Douglas IJ, Evans SJ, Pocock S, Smeeth L. The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. PLoS Med 2009; 6: e1000154.
24. Dorkhan M, Dencker M, Stagmo M, Groop L. Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes. Cardiovasc Diabetol 2009; 8: 15.
25. Chang AM, Maisel AS, Hollander JE. Diagnosis of heart failure. Heart Fail Clin 2009; 5: 25-35, vi.
26. Sambanis C, Tziomalos K, Kountana E, et al. Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes. Acta Diabetol 2008; 45: 23-30.
27. Scheen AJ, Tan MH, Betteridge DJ, Birkeland K, Schmitz O, Charbonnel B. Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17). Diabet Med 2009; 26: 1033-1039.
28. Retnakaran R, Zinman B. Thiazolidinediones and clinical outcomes in type 2 diabetes. Lancet 2009; 373: 2088-2090.